The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
Open accessAbstract
Synaptic dysfunction occurs early in senile dementias, presumably as a result of decreased levels of functional synaptic proteins as found in autopsied brains of patients with Alzheimer's disease (AD) or frontotemporal dementia (FTD). Plasma neuronal‐derived exosomes (NDEs) were recovered by precipitation and immunoabsorption from 12 patients with AD, 16 with FTD, and 28 controls in a cross‐sectional study, and from 9 patients with AD, 10with FTD, and 19 controls in a longitudinal study. Six synaptic proteins in NDE extracts were quantified by ELISAs and normalized for exosome amounts. NDE levels of synaptophysin, synaptopodin, synaptotagmin‐2, and neurogranin were significantly lower in patients with FTD and ADthan in controls, but those of growth‐associated protein 43 and synapsin 1 were reduced only in patients with AD. Functionally relevant phosphorylation of synapsin 1 serine 9 was reduced in patients with FTD and AD, although total synapsin 1 protein was higher in FTD than in controls. NDE levels of synaptotagmin, synaptophysin, and neurograninwere decreased yearsbeforedementia inpatientswithFTD and AD.NDElevelsof synaptopodin, synaptotagmin, and synaptophysin, but not of amyloid β‐peptide 42 or P‐T181‐tau, were correlated significantly with cognition assessed bymini‐mental state examination or AD assessment scale‐cognitive subscale. NDE synaptic proteins may be useful preclinical indices and progression measures in senile dementias.—Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A.M., Boxer, A., Miller, B. L. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. FASEB J. 30, 4141–4148 (2016). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ng is a postsynaptic protein that is important for maintaining synaptic plasticity and regulating calcium ion influxes, while SNAP25 is a presynaptic protein that plays a crucial role in synaptic vesicle fusion and neurotransmitter release, and both these proteins have been shown to play a key role in AD disease pathophysiology, although they may be less clinically relevant for FTD [10,[45][46][47”
In the citing paper
“Ng is a postsynaptic protein that is important for maintaining synaptic plasticity and regulating calcium ion influxes, while SNAP25 is a presynaptic protein that plays a crucial role in synaptic vesicle fusion and neurotransmitter release, and both these proteins have been shown to play a key role in AD disease pathophysiology, although they may be less clinically relevant for FTD [10,[45][46][47”
In the citing paper
“Ng is a postsynaptic protein that is important for maintaining synaptic plasticity and regulating calcium ion influxes, while SNAP25 is a presynaptic protein that plays a crucial role in synaptic vesicle fusion and neurotransmitter release, and both these proteins have been shown to play a key role in AD disease pathophysiology, although they may be less clinically relevant for FTD [10,[45][46][47”
In the citing paper
“there is a significant reduction of plasma neuronal-derived exosomal neurogranin in AD patients compared with the healthy controls.549”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [549]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Südhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547
Cited by
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In contrast, there is a significant reduction of plasma neuronal-derived exosomal neurogranin in AD patients compared with the healthy controls.(549) More importantly, the CSF neurogranin increases exclusively in AD patients and has not been observed in other neurodegenerative disorders, such as frontotemporal dementi…”
ResultCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., & Karamanos, Y. (2020) · Cells · doi:10.3390/cells9040851 · Cited by 503
Crosstalk Between Astrocytes and Microglia: An Overview
Matejuk, A., & Ransohoff, R. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01416 · Cited by 445
Mustapic, M., Eitan, E., Werner, J. K., Berkowitz, S. T., Lazaropoulos, M. P., Tran, J., Goetzl, E. J., & Kapogiannis, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00278 · Cited by 441
Self-citationExtracellular Vesicles and Neurodegenerative Diseases
Hill, A. F. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0147-18.2019 · Cited by 437
High complement levels in astrocyte‐derived exosomes of Alzheimer disease
Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., & Kapogiannis, D. (2018) · Annals of Neurology · doi:10.1002/ana.25172 · Cited by 370
Self-citationHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., et al. (2019) · doi:10.1101/806752 · Cited by 367
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Self-citationMechanisms of secretion and spreading of pathological tau protein
Brunello, C. A., Merezhko, M., Uronen, R.-L., & Huttunen, H. J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03349-1 · Cited by 304
Exosomes: roles and therapeutic potential in osteoarthritis
Ni, Z., Zhou, S., Li, S., Kuang, L., Chen, H., Luo, X., Ouyang, J., He, M., Du, X., & Chen, L. (2020) · Bone Research · doi:10.1038/s41413-020-0100-9 · Cited by 288
Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 258
Self-citationReich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Ge, X., Guo, M., Hu, T., Li, W., Huang, S., Yin, Z., Li, Y., Chen, F., Zhu, L., Kang, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.017 · Cited by 242
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
“5 pg/ml and 1117 ± 227 pg/ml, respectively) compared to the control group (2208 ± 354 pg/ml) [89].”
Kapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241
Self-citationSynaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach
Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D. (2018) · Brain · doi:10.1093/brain/awx352 · Cited by 220
“22 In line with this, SYT2 levels have also been shown to be decreased in plasma neuronal-derived exosomes (Goetzl et al., 2016).”
BackgroundTargeting the Synapse in Alzheimer’s Disease
Jackson, J., Jambrina, E., Li, J., Marston, H., Menzies, F., Phillips, K., & Gilmour, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00735 · Cited by 215
Imaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219
Self-citationFluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
New windows into the brain: Central nervous system-derived extracellular vesicles in blood
Shi, M., Sheng, L., Stewart, T., Zabetian, C. P., & Zhang, J. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.01.005 · Cited by 181
Quantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers
Smailovic, U., Koenig, T., Kåreholt, I., Andersson, T., Kramberger, M. G., Winblad, B., & Jelic, V. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.005 · Cited by 177
Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
D’Anca, M., Fenoglio, C., Serpente, M., Arosio, B., Cesari, M., Scarpini, E. A., & Galimberti, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00232 · Cited by 154
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Fluid biomarkers in frontotemporal dementia: past, present and future
Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122
Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases
Ciregia, F., Urbani, A., & Palmisano, G. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00276 · Cited by 110
“…enzyme 1, soluble amyloid precursor protein (sAPP)β, soluble Aβ42, sAPPα, glial-derived neurotrophic factor (GDNF), P-S396-tau, and P-T181-tau were significantly higher for patients, suggesting a role for activated astrocyte-neuron axis in proteinopathic dementias (Goetzl et al., 2016b).”
BackgroundMethodWinston, C. N., Romero, H. K., Ellisman, M., Nauss, S., Julovich, D. A., Conger, T., Hall, J. R., Campana, W., O’Bryant, S. E., Nievergelt, C. M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01005 · Cited by 105
Biomarker potential of brain‐secreted extracellular vesicles in blood in Alzheimer's disease
Badhwar, A., & Haqqani, A. S. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12001 · Cited by 87
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
Association of Aβ with ceramide-enriched astrosomes mediates Aβ neurotoxicity
Elsherbini, A., Kirov, A. S., Dinkins, M. B., Wang, G., Qin, H., Zhu, Z., Tripathi, P., Crivelli, S. M., & Bieberich, E. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00931-8 · Cited by 72
Xu, X., Iqbal, Z., Xu, L., Wen, C., Duan, L., Xia, J., Yang, N., Zhang, Y., & Liang, Y. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13610 · Cited by 68
Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease
Li, T.-R., Wang, X.-N., Sheng, C., Li, Y.-X., Li, F. Z.-T., Sun, Y., & Han, Y. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111175 · Cited by 60
Clarke, M. T. M., Brinkmalm, A., Foiani, M. S., Woollacott, I. O. C., Heller, C., Heslegrave, A., Keshavan, A., Fox, N. C., Schott, J. M., Warren, J. D., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0564-2 · Cited by 58
Synaptic Loss in Frontotemporal Dementia Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Malpetti, M., Jones, P. S., Cope, T. E., Holland, N., Naessens, M., Rouse, M. A., Rittman, T., Savulich, G., Whiteside, D. J., Street, D., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26543 · Cited by 53
Fan, M., Liu, S., Sun, H.-M., Ma, M.-D., Gao, Y.-J., Qi, C.-C., Xia, Q.-R., & Ge, J.-F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113375 · Cited by 50
Gao, X.-R., Chen, Z., Fang, K., Xu, J.-X., & Ge, J.-F. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01590-x · Cited by 47
Sogorb-Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01042-3 · Cited by 39
“A further study has also shown that neurogranin was significantly decreased in comparison with controls in plasma exosomes from people with FTD [32].”
ResultThe emerging double-edged sword role of exosomes in Alzheimer’s disease
Liang, T., Wu, Z., Li, J., Wu, S., Shi, W., & Wang, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1209115 · Cited by 37
Wang, X., Yang, H., Liu, C., & Liu, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1194210 · Cited by 36
Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid β production
Zoltowska, K. M., Maesako, M., Lushnikova, I., Takeda, S., Keller, L. J., Skibo, G., Hyman, B. T., & Berezovska, O. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0159-y · Cited by 36
Blood biomarkers in frontotemporal dementia: Review and meta-analysis
Ntymenou, S., Tsantzali, I., Kalamatianos, T., Voumvourakis, K. I., Kapaki, E., Tsivgoulis, G., Stranjalis, G., & Paraskevas, G. P. (2021) · Brain Sciences · doi:10.3390/brainsci11020244 · Cited by 31
“In particular, among the genotypes of rs5848 polymorphism, the TT genotype exhibits the lowest progranulin level followed by CT genotype and the CC genotype, which exhibits the highest level [37], whereas in the rs646776 polymorhism on SORT1, the CC genotype exhibits the lowest progranulin level followed by the CT gen…”
BackgroundSingh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03475-z · Cited by 28
In vivo exploration of synaptic projections in frontotemporal dementia
Salmon, E., Bahri, M. A., Plenevaux, A., Becker, G., Seret, A., Delhaye, E., Degueldre, C., Balteau, E., Lemaire, C., Luxen, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95499-1 · Cited by 21
Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review
Santos, F., Cabreira, V., Rocha, S., & Massano, J. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221141651 · Cited by 24
“Neuronal derived synaptic proteins were assessed in one study.(61) Goetzl et al showed decreased synaptotagmin (P = 0.”
BackgroundMonteiro-Reis, S., Carvalho-Maia, C., Bart, G., Vainio, S. J., Pedro, J., Silva, E. R., Sales, G., Henrique, R., & Jerónimo, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063267 · Cited by 21
Lizama, B. N., North, H. A., Pandey, K., Williams, C., Duong, D., Cho, E., Di Caro, V., Ping, L., Blennow, K., Zetterberg, H., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106575 · Cited by 19
Das, S., van Engelen, M.-P. E., Goossens, J., Jacobs, D., Bongers, B., Fieldhouse, J. L. P., Pijnenburg, Y. A. L., Teunissen, C. E., Vanmechelen, E., & Verberk, I. M. W. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01409-8 · Cited by 12
Small extracellular vesicles as potential theranostic tools in central nervous system disorders
Guo, M., Wang, L., Yin, Z., Chen, F., & Lei, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115407 · Cited by 4
Metadata
- Authors
- Goetzl, E. J., Kapogiannis, D., Schwartz, J. B., Lobach, I. V., Goetzl, L., Abner, E. L., Jicha, G. A., Karydas, A. M., Boxer, A., & Miller, B. L.
- Affiliations
- University of California, San Francisco (US)
- National Institute on Aging (US)
- Temple University (US)
- University of Kentucky (US)
- Corresponding author
- Goetzl, Edward J.
- ORCID
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2016-09-06
- Volume
- 30
- Issue
- 12
- Pages
- 4141-4148
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC5102122
- OpenAlex
- W2511373877
- Cited by
- 398
- References
- 40
- Citations by year
- 2026: 24 · 2025: 39 · 2024: 48 · 2023: 46 · 2022: 49 · 2021: 51 · 2020: 54 · 2019: 43 · 2018: 27 · 2017: 17
- FWCI
- 23.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Alzheimer's Association
- Alzheimer’s Research UK
- Weston Brain Institute
- National Institutes of Health
- National Institute on Aging (P30 AG028383)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- synaptic proteins, frontotemporal dementia, Alzheimer's disease, synaptophysin, synaptopodin, synaptotagmin 2, neurogranin, synapsin-1, growth-associated protein 43, plasma biomarkers, preclinical dementia, cognitive decline, synaptic dysfunction
- MeSH terms
- Alzheimer Disease, Cognition, Cross-Sectional Studies, Humans, Longitudinal Studies, Synapses, Biomarkers, Amyloid beta-Peptides, tau Proteins, Exosomes, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.